Branded

LINCOLNSHIRE, Ill. — The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

The two companies said the FDA had accepted their application for Bio-T-Gel and expected to complete its review by mid-November.

PLEASANTON, Calif. — Darren Singer, a 25-year GlaxoSmithKline veteran, has been named Safeway's SVP pharmacy, health and wellness, the retailer announced.

Singer will be responsible for retail pharmacy operations, specialty care, pharmacy services, compliance, benefit management and managed care for Safeway. He will report to Safeway's merchandising president, Kelly Griffith.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a treatment made by Merck for treating skin cancer, Merck said Monday.

Merck announced the approval of Sylatron (peginterferon alfa-2b) as an add-on treatment for treating melanoma with microscopic of gross nodal involvement within 84 days of surgery.

JERUSALEM — An investigational drug made by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis reduced disease relapses and prevented the progression of disability, according to late-stage clinical trial results announced Monday.

ST. LOUIS — The road to waste reduction is paved with good intentions.

That’s the conclusion of pharmacy benefit manager Express Script’s "2010 Drug Trend Report," which found that 33% of annual pharmacy-related waste can be eliminated by encouraging patients to improve common behaviors linked to their prescription drugs by harnessing their good intentions.

CHADDS FORD, Pa. — Endo Pharmaceuticals will buy American Medical Systems for $2.9 billion, the drug maker said Monday.

Endo said it and AMS had reached an agreement whereby Endo would acquire the maker of devices and therapies for pelvic health for $30 per share. AMS’ business focuses on men’s health, women’s health and benign prostatic hyperplasia.

TITUSVILLE, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating schizophrenia in adolescents.

J&J said Monday that the FDA had approved Invega (paliperidone) extended-release tablets for patients ages 12 to 17 years. The drug is marketed by J&J subsidiary Ortho-McNeil-Janssen Pharmaceuticals. The drug originally was approved in 2006 for treating schizophrenia in adults.

PARIS — Genzyme now officially is a wholly owned subsidiary of Sanofi-Aventis.

The Paris-based drug maker said that the closing followed the completion of the exchange offer for drug maker Genzyme last week. As its subsidiary, Genzyme will become a new platform in Sanofi's sustainable growth strategy and expand the company's presence in biotechnology, Sanofi said. Genzyme will continue to operate out of its Cambridge, Mass., headquarters, and will be led by Sanofi CEO Christopher Viehbacher for several months.